Nationwide
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
Hoffmann-La Roche
Ph 2·~5yr·9 sites in CA, CO, FL +5
Showing 1–24 of 91 trials
Hoffmann-La Roche
Genentech, Inc.
Hoffmann-La Roche
University of California, San Francisco
University of Kansas Medical Center
Accelerated Cure Project for Multiple Sclerosis
University of Southern California
University of Illinois at Chicago
University of Kansas Medical Center
University of Illinois at Chicago
University of Illinois at Chicago
Marquette University
University of Illinois at Chicago
Kessler Foundation
Tiffany J. Braley, MD, MS
University of Washington
Oklahoma Medical Research Foundation
Johns Hopkins University
Tr1X, Inc.
Icahn School of Medicine at Mount Sinai